摘要
目的研究西酞普兰联合利培酮治疗躯体形式障碍(SD)的疗效及其安全性。方法101例躯体形式障碍患者随机分为2组,研究组予以西酞普兰合并利培酮治疗,对照组单用西酞普兰治疗,疗程均为8周。治疗前与治疗后第2、4、6、8周采用症状自评量表(SCL-90)、汉密尔顿抑郁量表(HAMD)评定临床疗效,不良反应症状量表(TESS)评定不良反应。结果治疗后2组SCL-90、HAMD评分较治疗前减少,差异有统计学意义(P<0·01),8周末研究组有效率82%,对照组54%,2组差异有统计学意义(P<0·05),并且在治疗2周末研究组较对照组显效快,差异有统计学意义(P<0·05)。2组不良反应均表现较轻,大多出现在治疗的早期,经对症治疗逐渐缓解。结论西酞普兰联合利培酮治疗躯体形式障碍较单用西酞普兰疗效好,起效快,且不增加不良反应。
Objective To study the efficacy and safety of citalopram combined with risperidone in the treatment of somatoform disorders.Methods 101 patients were assigned to citalopram（control group,n=51）and citalopram combined with risperidone（study group,n=50）,and treated for 8 weeks.Before treatment and at the ends of the week2、4、6、8,the clinical effects and side effects were assessed with SCL-90,HAMD,TESS.Results The score of SCL-90 and HAMD after the treatment of the study group and control group were lower than before treatment, which had a significant difference（P〈0.01）.At the end of 8th week,effective rates of the study group and control group were respectively 82%and 54%,which had a significant difference（P〈0.01）.There was difference in the effective time of drugs of the two groups（P〈0.01）.Side effects of both the two group were milder,most occurred in the initial stage of treatment and gradually remitted via expectant treatment.Conclusion citalopram combined with risperidone in treatment of somatoform disorders takes effects better and faster than single citalopram and doesn＇t increase side effects.
出处
《中国实用医药》
2008年第15期33-34,共2页
China Practical Medicine
